result
clinic
studi
use
intraven
iv
ribavirin
treat
depart
defens
personnel
hemorrhag
fever
renal
syndrom
hfr
acquir
korea
review
determin
clinic
cours
hfr
treat
iv
ribavirin
total
individu
enrol
studi
subsequ
serolog
confirm
hfr
four
individu
receiv
three
fewer
dose
ribavirin
exclud
treatment
analysi
remain
individu
oliguria
present
one
individu
treatment
initi
none
remain
subject
develop
oliguria
requir
dialysi
mean
peak
serum
creatinin
mgdl
occur
day
ribavirin
therapi
peak
serum
creatinin
onset
polyuria
occur
mean
day
ill
revers
hemolyt
anemia
main
advers
event
ribavirin
decreas
hematocrit
observ
individu
inabl
adjust
baselin
variabl
prevent
comparison
histor
cohort
korea
oliguria
report
case
dialysi
requir
approxim
hfr
case
caus
hantaan
viru
occurr
oliguria
dialysi
requir
treatment
cohort
support
previou
placebocontrol
hfr
trial
china
iv
ribavirin
given
earli
result
decreas
occurr
oliguria
decreas
sever
renal
insuffici
publish
elsevi
bv
jm
rusnak
area
asia
east
ural
mountain
caus
primarili
two
hantavirus
hantaan
viru
seoul
viru
lee
hantaan
viru
carri
stripe
field
mous
apodemu
agrariu
seen
primarili
rural
area
associ
sever
form
diseas
mortal
rate
rang
korea
lee
bruno
et
al
kim
et
al
seoul
viru
carri
domest
rat
rattu
norvegicu
rattu
rattu
respons
urban
case
hfr
seoul
viru
gener
associ
less
sever
form
diseas
mortal
rate
less
hfr
diseas
character
fever
headach
abdomin
andor
back
pain
renal
insuffici
mild
manifest
hemorrhag
diseas
may
manifest
five
clinic
phase
ill
febril
hypotens
oligur
polyur
convalesc
phase
lee
bruno
et
al
kim
et
al
nearli
individu
present
febril
ill
person
develop
hypotens
develop
oliguria
urin
output
less
ml
per
day
gener
last
day
individu
see
front
matter
publish
elsevi
bv
hemorrhag
fever
renal
syndrom
hfr
caus
hantavirus
famili
bunyavirida
hfr
korea
china
opinion
interpret
conclus
recommend
author
necessarili
endors
us
armi
articl
cowritten
offic
employe
us
govern
part
offici
duti
therefor
subject
us
copyright
research
human
subject
conduct
complianc
dod
feder
state
statut
regul
relat
protect
human
subject
adher
principl
identifi
belmont
report
data
human
subject
research
gather
conduct
public
irb
approv
protocol
est
risk
hypertens
pulmonari
edema
complic
renal
insuffici
oligur
phase
result
dialysi
approxim
hfr
case
due
hantaan
case
due
seoul
viru
caus
death
mainli
due
complic
renal
insuffici
shock
hemorrhag
treatment
consist
support
care
care
manag
fluid
control
blood
pressur
dialysi
requir
iv
ribavirin
investig
nucleosid
analogu
demonstr
vitro
activ
hantavirus
huggin
random
doubleblind
placebocontrol
trial
china
conduct
demonstr
treatment
iv
ribavirin
earli
diseas
associ
decreas
morbid
mortal
hfr
huggin
et
al
intraven
iv
ribavirin
made
avail
protocol
investig
drug
treat
hfr
depart
defens
dod
medic
treatment
facil
control
group
deem
ethic
base
decreas
mortal
report
china
studi
clinic
experi
iv
ribavirin
treat
hfr
acquir
korea
review
assess
clinic
cours
hfr
treat
iv
ribavirin
safeti
profil
ribavirin
treat
hfr
studi
conduct
gener
hospit
seoul
korea
korea
us
naval
medic
center
okinawa
japan
individu
year
old
older
elig
enrol
provid
onset
fever
within
past
day
either
met
specif
inclus
criteria
probabl
case
hfr
clinic
syndrom
consist
hfr
meet
criteria
epidemiolog
histori
possibl
exposur
hantaviru
probabl
case
hfr
defin
fever
f
least
two
follow
symptom
headach
pain
abdomen
back
flank
nausea
vomit
one
physic
exam
find
suggest
vascular
instabl
vascular
fragil
facial
flush
facial
perioribit
edema
conjunctiv
inject
petechia
least
one
follow
laboratori
find
thrombocytopenia
proteinuria
elev
serum
creatinin
known
sever
reaction
ribavirin
exclus
criterion
iv
ribavirin
valeant
pharmaceut
costa
mesa
ca
manufactur
gensiasicor
pharmaceut
inc
irvin
ca
given
cours
initi
iv
load
dose
mgkg
maxim
dose
g
follow
dose
mgkg
everi
h
total
dose
maximum
dose
g
h
initi
day
therapi
mgkg
everi
h
total
dose
maximum
dose
g
h
next
day
drug
administ
ml
normal
salin
infus
min
histori
physic
exam
perform
baselin
daili
throughout
treatment
cours
baselin
pregnanc
test
obtain
women
baselin
daili
laboratori
test
includ
complet
blood
count
serum
electrolyt
renal
liver
function
test
serum
albumin
total
serum
protein
prothrombin
time
activ
partial
thromboplastin
time
urinalysi
individu
discharg
hospit
complet
iv
ribavirin
cours
clinic
stabl
mandatori
followup
laboratori
test
day
clinic
indic
daili
electrocardiogram
cardiac
monitor
requir
treatment
occurr
junction
bradycardia
tempor
relat
ribavirin
one
subject
daili
pancreat
enzym
obtain
begin
serum
magnesium
calcium
uric
acid
level
begin
investig
serolog
test
antibodyspecif
igm
elisa
hantaan
viru
use
confirm
hfr
diagnosi
serolog
test
obtain
baselin
subsequ
day
test
perform
gener
hospit
seoul
confirm
usamriid
procedur
antibodyspecif
igm
elisa
describ
previou
public
leduc
et
al
subject
serolog
confirm
hfr
includ
analysi
epidemiolog
clinic
present
subject
receiv
least
four
dose
iv
ribavirin
includ
analysi
clinic
cours
diseas
safeti
clinic
cours
analysi
assess
occurr
oliguria
number
subject
requir
dialysi
mean
peak
serum
creatinin
mean
day
occurr
peak
serum
creatinin
onset
polyuria
hemorrhag
manifest
nadir
platelet
count
death
total
person
serolog
confirm
hfr
acquir
korea
enrol
studi
gener
hospit
korea
one
us
navi
medic
center
okinawa
individu
predominantli
male
mean
age
year
tabl
histori
field
duti
korea
within
previou
day
determin
case
suggest
hantaan
viru
due
exposur
excreta
field
mice
caus
hfr
number
case
rang
zero
seven
case
per
year
diseas
observ
throughout
year
hfr
season
case
occur
octob
decemb
antibodyspecif
igm
elisa
hantaan
viru
posit
patient
first
specimen
obtain
initi
titer
obtain
mean
day
ill
rang
day
fever
rang
day
ill
histori
fever
obtain
subject
initi
iv
ribavirin
tabl
day
onset
fever
day
onset
ill
coincid
person
fever
develop
later
individu
oligur
day
iv
ribavirin
one
oligur
individu
receiv
three
dose
ribavirin
due
transfer
anoth
hospit
dialysi
includ
treatment
analysi
data
avail
determin
oliguria
present
two
sever
ill
individu
die
within
h
receiv
first
dose
iv
ribavirin
receiv
one
two
dose
ribavirin
includ
treatment
analysi
b
epistaxi
six
person
rang
day
onset
ill
thrombocytopenia
proteinuria
present
subject
elev
serum
creatinin
person
initi
ribavirin
case
definit
probabl
hfr
met
subject
subject
fever
f
abnorm
laboratori
find
either
thrombocytopenia
proteinuria
elev
serum
creatinin
histori
two
follow
symptom
headach
pain
abdomen
back
flank
nauseavomit
observ
find
vascular
fragil
instabl
individu
iv
ribavirin
initi
day
fever
day
ill
mean
day
ribavirin
initi
day
fever
ill
fig
four
individu
receiv
one
three
dose
iv
ribavirin
exclud
analysi
clinic
cours
two
subject
sever
diseas
mimick
septic
shock
die
within
h
ribavirin
initi
two
subject
transfer
anoth
hospit
renal
insuffici
dialysi
requir
one
individu
present
oliguria
serum
creatinin
mgml
tabl
clinic
symptom
laboratori
test
person
treatment
analysi
cohort
time
iv
ribavirin
initi
mean
day
ill
list
tabl
individu
complet
full
cours
iv
ribavirin
therapi
individu
receiv
dose
ribavirin
reason
earli
discontinu
ribavirin
eight
individu
list
tabl
oliguria
present
one
individu
initi
ribavirin
none
remain
individu
develop
oliguria
requir
dialysi
person
normal
pretreat
serum
creatinin
mean
baselin
serum
creatinin
mgdl
rang
mgdl
creatinin
remain
normal
throughout
cours
ill
individu
tabl
mean
peak
serum
creatinin
mgdl
rang
mgdl
occur
day
iv
ribavirin
therapi
fig
mean
time
occurr
peak
serum
creatinin
onset
polyuria
day
ill
rang
daya
ill
peak
serum
creatinin
day
ill
onset
polyuria
polyuria
last
mean
durat
day
rang
day
fig
hypotens
defin
systol
blood
pressur
less
mm
mercuri
present
two
individu
iv
ribavirin
initi
manag
fluid
vasopressor
resolv
within
h
hypotens
phase
observ
remain
individu
increas
platelet
count
observ
day
ribavirin
initi
individu
fig
mean
time
nadir
platelet
count
day
ribavirin
therapi
rang
day
day
ill
rang
day
fig
platelet
count
less
mm
note
patient
patient
platelet
count
less
mm
petechia
present
individu
present
seven
individu
ribavirin
initi
five
individu
develop
petechia
initi
ribavirin
two
individu
develop
ecchymos
five
individu
experienc
mild
bleed
four
individu
mild
epistaxi
one
individu
mild
bleed
appendectomi
venipunctur
site
sever
hemorrhag
result
systol
blood
pressur
less
mm
hemorrhag
shock
observ
howev
one
death
due
respiratori
failur
unclear
etiolog
moder
tabl
baselin
symptom
examin
laboratori
test
day
iv
ribavirin
initi
day
ribavirin
individu
treatment
analysi
cohort
clinic
symptom
laboratori
test
n
sever
respiratori
failur
present
iv
ribavirin
initi
associ
sudden
decreas
hemoglobin
previou
h
without
overt
evid
bleed
individu
die
day
iv
ribavirin
therapi
due
sudden
deterior
respiratori
symptom
min
requir
intub
subsequ
cardiopulmonari
resuscit
death
treatment
cohort
person
main
advers
event
observ
iv
ribavirin
revers
hemolyt
anemia
anemia
hematocrit
observ
individu
person
greater
decreas
hematocrit
two
four
case
world
health
organ
grade
anemia
toxic
attribut
secondari
iv
ribavirin
fig
rash
neck
upper
chest
observ
one
individu
infus
dose
ribavirin
resolv
within
h
administr
diphenhydramin
benadryl
mg
intramuscularli
rash
recur
infus
dose
premed
diphenhydramin
ribavirin
discontinu
tabl
asymptomat
bradyarrhythmia
observ
three
case
tabl
first
case
occur
individu
develop
asymptomat
bradycardia
beatsmin
day
iv
ribavirin
progress
asymptomat
junction
bradycardia
beatsmin
day
therapi
ribavirin
discontinu
total
dose
receiv
bradyarrhythmia
resolv
within
h
protocol
subsequ
requir
cardiac
monitor
andor
daili
ekg
therapi
two
individu
develop
intermitt
asymptomat
period
h
sinu
bradycardia
low
beatsmin
begin
day
ribavirin
therapi
discontinu
ribavirin
receiv
dose
dose
respect
bradycardia
resolv
individu
within
h
possibl
tempor
relationship
bradyarrhythmia
iv
ribavirin
rais
concern
potenti
bradyarrhythmia
iv
ribavirin
none
three
individu
sever
renal
insuffici
peak
serum
creatinin
rang
mgdl
suggest
presenc
higher
ribavirin
level
abnorm
baselin
amylas
note
person
baselin
amylas
level
perform
elev
serum
amylas
subsequ
observ
remain
person
occur
mean
day
rang
day
ribavirin
therapi
five
person
exhibit
toxic
amylas
uml
two
individu
ribavirin
discontinu
prematur
elev
pancreat
enzym
tabl
one
individu
elev
pancreat
enzym
abdomin
pain
initi
iv
ribavirin
amylas
decreas
day
ribavirin
therapi
receiv
dose
subject
also
receiv
highdos
intraven
methylprednisolon
elev
uric
acid
observ
individu
serum
uric
acid
test
perform
cours
ribavirin
individu
peak
uric
acid
greater
mgdl
mean
peak
uric
acid
level
mgdl
rang
mgdl
occur
day
ribavirin
individu
asymptomat
hyperuricemia
hypocalcemia
correct
low
albumin
hypomagnesaemia
observ
commonli
initi
iv
ribavirin
individu
respect
supplement
calcium
magnesium
administ
individu
respect
pathogenesi
hfr
unknown
like
immun
mediat
igm
antibodi
hantaan
viru
circul
lymphoblast
present
onset
symptom
peter
et
al
kanerva
et
al
lewi
et
al
renal
insuffici
like
caus
proinflammatori
mediat
gener
host
immun
respons
viru
takala
et
al
kanerva
et
al
cosgriff
peter
et
al
mustonen
et
al
sever
diseas
may
depend
upon
speci
hantaviru
virul
hantaviru
strain
exposur
dose
major
histocompat
complex
host
huggin
et
al
kompanet
et
al
peter
et
al
mustonen
et
al
mustonen
et
al
lower
death
rate
rang
report
diseas
manag
healthcar
provid
experienc
treat
hfr
andor
dialysi
avail
smadel
kim
et
al
iv
ribavirin
demonstr
decreas
sever
diseas
hfr
anim
diseas
sever
correl
viral
burden
zhang
et
al
zhang
et
al
suckl
mice
infect
hantaan
viru
treat
ribavirin
either
onset
viremia
day
appear
viral
antigen
tissu
day
decreas
sever
ill
increas
surviv
huggin
et
al
day
viral
titer
organ
treat
anim
lower
control
anim
ribavirintr
mice
also
lower
level
viremia
random
doubleblind
placebocontrol
clinic
trial
china
china
iv
ribavirin
given
within
day
fever
onset
associ
decreas
occurr
oliguria
decreas
sever
renal
insuffici
earlier
onset
peak
serum
creatinin
polyuria
decreas
hemorrhag
manifest
diseas
compar
nonribavirin
treat
control
huggin
et
al
decreas
mortal
observ
ribavirintr
subject
versu
nonribavirin
treat
control
sevenfold
decreas
mortal
adjust
baselin
variabl
dialysi
avail
studi
mechan
ribavirin
prevent
death
like
due
prevent
oliguria
death
associ
prolong
oliguria
antivir
activ
iv
ribavirin
may
due
multipl
mechan
recent
data
suggest
ribavirin
may
exert
primari
activ
hantaan
viru
serv
rna
viru
mutagen
result
extinct
catastroph
error
result
incorpor
viral
rna
genom
huggin
chung
et
al
comparison
iv
ribavirintr
cohort
histor
nonribavirin
treat
hfr
control
korea
limit
adjust
made
variabl
may
influenc
diseas
sever
ie
demograph
subject
hantaviru
strain
exposur
dose
may
influenc
yearli
infect
rodent
popul
treatment
variabl
vaccin
statu
howev
cohort
compris
republ
korea
rok
militari
troop
mainli
young
adult
male
hospit
mean
day
ill
hfr
medic
referr
center
dialysi
capabl
experienc
clinician
oliguria
observ
dialysi
requir
tabl
review
occurr
oliguria
dialysi
requir
mean
time
peak
serum
creatinin
sever
renal
failur
death
iv
ribavirintr
hfr
cohort
vs
histor
nonribavirintr
hfr
control
korea
individu
kim
et
al
tabl
time
onset
symptom
admiss
similar
oligur
nonoligur
group
individu
develop
oliguria
subsequ
requir
dialysi
nonoligur
person
requir
dialysi
mean
peak
serum
creatinin
oligur
patient
mgdl
occur
mean
day
ill
rang
day
onset
oliguria
occur
mean
day
ill
rang
day
last
mean
durat
day
rang
day
nonoligur
patient
mean
peak
serum
creatinin
mgdl
occur
mean
day
ill
rang
day
hfr
case
receiv
hantaviru
vaccin
protect
effect
vaccin
prevent
oliguria
observ
experi
rok
cohort
report
kim
similar
earlier
unvaccin
hfr
cohort
compris
patient
admit
central
armi
hospit
patient
seoul
nation
univers
hospit
oliguria
report
hfr
case
due
hantaan
viru
dialysi
requir
case
creatinin
valu
greater
mgdl
case
lee
tabl
onset
oliguria
hfr
hantaan
viru
gener
occur
day
ill
last
day
rang
day
peak
serum
creatinin
gener
observ
day
ill
onset
polyuria
late
second
week
ill
day
ill
public
hfr
due
seoul
viru
associ
oliguria
patient
dialysi
requir
case
serum
creatinin
greater
mgdl
case
experi
us
dod
cohort
hfr
acquir
korea
korea
use
iv
ribavirin
mainli
young
adult
male
treat
us
dod
medic
facil
dialysi
avail
similar
korean
hfr
cohort
oliguria
occur
hfr
case
bruno
et
al
tabl
oliguria
last
mean
durat
day
rang
day
onset
polyuria
gener
occur
later
second
week
ill
dialysi
requir
case
comparison
ribavirintr
hfr
cohort
histor
control
cohort
made
due
limit
adjust
differ
baselin
demograph
variabl
may
influenc
diseas
progress
oliguria
one
subject
present
initi
ribavirin
dialysi
requir
none
subject
treatment
cohort
lower
oliguria
dialysi
requir
observ
nonribavirintr
hfr
cohort
korea
lee
bruno
et
al
kim
et
al
similar
time
period
dialysi
requir
two
korean
cohort
remain
unchang
addit
mean
peak
serum
creatinin
lower
mgdl
maximum
creatinin
mgdl
peak
serum
creatinin
onset
polyuria
mean
day
ill
occur
earlier
histor
report
similar
ribavirintr
cohort
three
nonribavirin
treat
cohort
also
compris
mainli
young
adult
male
ribavirintr
cohort
manag
hospit
dialysi
referr
capabl
clinic
experi
ribavirintr
cohort
suggest
iv
ribavirin
may
associ
decreas
oliguria
occurr
renal
diseas
sever
report
iv
ribavirin
hfr
treatment
trial
perform
china
provid
support
need
second
placebocontrol
studi
goal
fda
approv
drug
huggin
et
al
concern
higher
death
rate
nonribavirin
treat
hfr
control
group
make
control
group
uneth
may
appli
popul
dialysi
capabl
death
rate
ribavirin
treatment
cohort
similar
death
rate
report
nonribavirin
hfr
cohort
korea
dialysi
avail
lee
kim
et
al
tabl
sever
thrombocytopenia
attribut
primarili
increas
platelet
consumpt
dissemin
intravascular
coagulopathi
well
defect
platelet
function
may
contribut
problem
hemostasi
hfr
guang
et
al
kanerva
et
al
cosgriff
trend
toward
increas
platelet
count
decreas
hemorrhag
manifest
diseas
observ
ribavirintr
hfr
patient
compar
nonribavirin
treat
control
huggin
et
al
thrombocytosi
attribut
ribavirin
observ
rhesu
macaqu
argentin
hemorrhag
fever
ahf
treat
iv
ribavirin
mckee
et
al
studi
suggest
mechan
increas
platelet
count
stimul
platelet
product
base
increas
megakarocty
ploidi
observ
ribavirintr
macaqu
aggreg
studi
suggest
platelet
function
normal
increas
normalfunct
platelet
could
result
potenti
hemostasi
benefit
hfr
occurr
nadir
platelet
count
mean
day
ribavirin
increas
platelet
count
individu
day
ribavirin
initi
cohort
suggest
possibl
tempor
relat
platelet
increas
ribavirin
nadir
platelet
count
mean
day
ill
ribavirintr
cohort
similar
rok
nonribavirin
treat
militari
cohort
mean
day
oligur
patient
mean
day
nonoligur
patient
kim
et
al
earlier
report
two
nonribavirin
treat
hfr
cohort
day
earli
second
week
ill
lee
bruno
et
al
petechia
observ
case
ecchymos
case
hfr
acquir
korea
lee
bruno
et
al
percentag
individu
hemorrhag
manifest
hfr
ribavirintr
cohort
petechia
ecchymos
mild
bleed
sever
hemorrhag
lower
histor
report
decreas
risk
hemorrhag
due
ribavirin
assess
without
control
group
revers
hemolyt
anemia
common
wellknown
side
effect
ribavirin
common
advers
event
observ
occurr
greater
reduct
hematocrit
individu
cohort
higher
observ
china
ribavirintr
cohort
observ
onethird
hfr
subject
receiv
iv
ribavirin
huggin
et
al
similar
cohort
receiv
iv
ribvirin
hantapulmonari
syndrom
hp
sever
acut
respiratori
syndrom
sar
chapman
et
al
chapman
et
al
chiou
et
al
knowl
et
al
muller
et
al
koren
et
al
mcevoy
et
al
anemia
well
toler
hfr
cohort
compris
mainli
young
healthi
adult
howev
ribavirin
use
caution
individu
medic
condit
coronari
arteri
diseas
congest
heart
failur
chf
anemia
may
toler
three
bradyarrhythmia
seen
cohort
like
hfr
iv
ribavirin
bradycardia
hfr
report
numer
public
occur
individu
hfr
four
hantavirus
caus
hfr
commonli
oligur
polyur
phase
day
ill
amitina
pimenov
et
al
puljiz
et
al
katetanov
et
al
cardiac
abnorm
report
hfr
includ
nonspecif
cardiac
conduct
abnorm
atrial
fibril
junction
bradycardia
first
second
degre
atrioventricular
av
block
prematur
atrial
ventricular
contract
sinu
tachycardia
depress
left
ventricular
function
myocard
markot
et
al
puljiz
et
al
chun
godfrey
pal
et
al
basin
et
al
liu
et
al
katetanov
et
al
pimenov
et
al
ekg
abnorm
report
case
hfr
acquir
croatia
either
dobrava
puumala
virus
electrolyt
metabol
disturb
found
statist
differ
patient
abnorm
ekg
puljiz
et
al
autopsi
report
demonstr
cardiac
find
hemorrhag
edema
mainli
right
atrium
mononuclear
cell
infiltr
mainli
left
atrium
throughout
heart
luke
hullinghorst
steer
kessler
suggest
cardiac
abnorm
may
direct
effect
hantaviru
tempor
resolut
bradyarrhythmia
within
h
ribavirin
cessat
cohort
may
reflect
natur
bradyarrhythmia
hfr
gener
selflimit
occur
mainli
oliguria
phase
higher
drug
level
felt
present
three
case
bradyarrhythmia
serum
creatinin
level
mildli
elev
ribavirin
associ
cardiotox
cardiac
effect
preclin
anim
trial
involv
dog
monkey
rat
myocard
observ
initi
studi
four
subsequ
studi
rat
ribavirin
investig
brochur
howev
recent
retrospect
analysi
sar
patient
show
treatment
iv
ribavirin
associ
increas
risk
bradycardia
heart
rate
beatsmin
muller
et
al
possibl
ribavirin
may
potenti
bradycardia
assess
without
placebocontrol
studi
nucleosid
analogu
associ
pancreat
possibl
determin
ribavirin
may
caus
potenti
pancreat
hyperamylasemia
without
placebocontrol
studi
pancreat
known
complic
hfr
present
one
third
hfr
autopsi
korean
conflict
hullinghorst
steer
patient
sar
receiv
iv
ribavirin
increas
risk
pancreat
elev
pancreat
enzym
multivari
analysi
although
elev
amylas
level
pancreat
occur
frequent
univari
analysi
muller
et
al
hyperamylasemia
pancreat
observ
seroneg
seroposit
individu
given
iv
ribavirin
possibl
hp
suggest
either
enrol
bia
drug
induc
etiolog
chapman
et
al
chiou
et
al
pancreat
enzym
follow
individu
hfr
discontinu
ribavirin
may
consid
person
develop
pancreat
hyperuricemia
report
case
hypocalcemia
hypomagnesemia
high
case
hfr
treat
ribavirin
determin
made
studi
concern
potenti
laboratori
abnorm
iv
ribavirin
lee
mustonen
et
al
mild
hyperuricemia
associ
ribavirin
possibl
reflect
metabol
ribavirin
urat
investig
brochur
uric
acid
level
cohort
commonli
mgdl
high
mgdl
subject
develop
symptom
hyperuricemia
retrospect
analysi
cohort
sar
show
patient
receiv
iv
ribavirin
statist
like
develop
hypomagnesemia
possibl
hypocalcemia
suggest
iv
ribavirin
may
perhap
potenti
hypomagnesemia
hypocalcemia
muller
et
al
mcevoy
et
al
direct
comparison
cohort
histor
nonribavirin
treat
hfr
control
possibl
due
inabl
adjust
baselin
demograph
variabl
may
influenc
diseas
sever
clinic
experi
observ
iv
ribavirin
treatment
hfr
us
dod
cohort
korea
oliguria
dialysi
requir
treatment
cohort
suggest
administr
iv
ribavirin
earli
hfr
may
decreas
renal
complic
hfr
report
initi
iv
ribavirin
trial
china
ethic
concern
perform
second
placebocontrol
trial
may
also
address
studi
death
rate
cohort
similar
nonribavirin
treat
hfr
cohort
korea
dialysi
avail
suggest
dialysi
may
prevent
death
relat
sever
renal
insuffici
possibl
prevent
iv
ribavirin
china
studi
main
advers
event
iv
ribavirin
revers
hemolyt
anemia
common
may
sever
associ
ribavirin
advers
event
hypocalcemia
hypomagnesemia
hyperuricemia
pancreat
bradycardia
unclear
abnorm
also
complic
hfr
studi
support
need
random
placebocontrol
studi
assess
iv
ribavirin
treat
hfr
support
fda
approv
drug
